MITO 35b
Olaparib beyond progression compared to platinum chemotherapy after secondary cytoreductive surgery in recurrent ovarian cancer patients. The phase III randomized, open label MITO 35b study: a project of the MITO-MANGO groups.
Centro Coordinatore: Istituto Nazionale Tumori Fondazione G. Pascale
Principal Investigator: Sandro Pignata, Stefano Greggi
Sub Investigator: -
Study Coordinator: Clorinda Schettino, Francesco Perrone
Raccolta dati ancora in corso
Tipologia Studio
Osservazionale
Patologie
Ovaio